JDP2

Across TCGA pan-cancer cohorts, JDP2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of JDP2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where JDP2 RNA is repressed in tumor relative to normal tissue. In most cancer types JDP2 is over-expressed in tumor, although a few such as LUAD and BLCA show the opposite, repressed pattern.

LUAD, BLCA, and KIRP are the cancer types where JDP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in JDP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−1.358	<.001	11	view →
BLCA	Male	All	−1.444	<.001	10	view →
KIRP	All	II,III,IV	−0.871	<.001	9	view →
KICH	Female	II,III,IV	−2.191	<.001	8	view →
THCA	All	II,III,IV	−0.578	<.001	7	view →
LIHC	All	All	−0.549	<.001	7	view →
LUSC	Male	II,III,IV	−1.759	<.001	6	view →
BRCA	All	II,III,IV	−0.574	<.001	6	view →
COAD	All	II,III,IV	−0.342	<.001	6	view →
PRAD	All	All	−0.876	<.001	2	view →
READ	All	All	−0.612	.027	1	view →
ESCA	Male	All	+0.605	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

JDP2–LUAD

Open the LUAD breakdown →